CDK7 is a novel therapeutic target in fibrolamellar carcinoma
Manabu Nukaya1, Patrick R Carney1, Crystal Cafferty1
1Department of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Abstract:
Fibrolamellar Carcinoma (FLC) is a rare and deadly cancer that arises in young, otherwise healthy patients. For patients that cannot be treated with surgery, only 30%-45% survive to 5 years with current treatment options. These poor survival odds highlight the need for new therapeutic targets. Using patient samples, we identified that abnormal function of cyclin-dependent kinase 7 (CDK7) is a key component of pathways that are essential for FLC cancer cell identity and survival. Consequently, drug inhibitors of CDK7 suppressed these abnormal pathways and also caused cancer cell death in a dose-dependent manner. This held true in several patient-derived models of FLC. We then found that inhibition of CDK7 can combine with other drug candidates to increase the therapeutic response in FLC cells. Taken together, this suggests CDK7 is a promising target for future treatment in human FLC.
Insights
Targeting cyclin-dependent kinase 7 (CDK7) shows promise for treating rare Fibrolamellar Carcinoma (FLC). Inhibiting CDK7 can kill FLC cancer cells and improve treatment responses, offering new hope for patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Fibrolamellar Carcinoma (FLC) is a rare, aggressive liver cancer predominantly affecting young adults.
- Current treatments for unresectable FLC offer limited survival benefits, with 5-year survival rates between 30-45%.
- There is a critical unmet need for novel therapeutic strategies and drug targets in FLC.
Purpose of the Study:
- To investigate the role of cyclin-dependent kinase 7 (CDK7) in FLC pathogenesis.
- To evaluate the therapeutic potential of CDK7 inhibition in FLC models.
- To explore combination therapies involving CDK7 inhibitors for enhanced FLC treatment.
Main Methods:
- Analysis of patient-derived FLC samples to identify key molecular pathways.
- Utilizing patient-derived FLC models to test the efficacy of CDK7 inhibitors.
- Dose-response studies to assess cancer cell death upon CDK7 inhibition.
- Investigating the synergistic effects of CDK7 inhibitors with other drug candidates.
Main Results:
- Abnormal CDK7 function was identified as crucial for FLC cell identity and survival.
- CDK7 inhibition effectively suppressed oncogenic pathways essential for FLC.
- Pharmacological inhibition of CDK7 led to dose-dependent FLC cancer cell death in vitro and in patient-derived models.
- Combined inhibition of CDK7 with other agents demonstrated increased therapeutic efficacy.
Conclusions:
- CDK7 is a critical driver of FLC and represents a promising therapeutic target.
- Targeting CDK7 offers a potential new treatment strategy for patients with Fibrolamellar Carcinoma.
- Combination therapies involving CDK7 inhibitors may enhance treatment outcomes for FLC.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...